4.8mg Wegovy: does this dose exist, and what should you know?

Where does 4.8mg come from if it isn't a real Wegovy dose?

This is a fair question, and the most honest answer is: probably nowhere reputable. The licensed Wegovy strengths (0.25mg, 0.5mg, 1mg, 1.7mg and 2.4mg) are the only semaglutide doses approved by the MHRA for weight management as a weekly injection. A figure like 4.8mg doesn't correspond to any step in the titration schedule, any pen format, or any published trial arm for Wegovy.

One common misconception is that doses can simply be doubled or combined to speed up results. They can't. Each pen delivers a fixed, pre-set amount, and the titration schedule exists for clinical reasons, primarily to let the body adjust and to keep gastrointestinal side effects manageable. A prescriber won't authorise a dose that falls outside the licensed range.

It's possible the figure appears in online discussions where people confuse weekly doses with cumulative amounts, or where sellers are describing unlicensed or compounded products. The MHRA has warned about counterfeit and unlicensed weight-loss injectables circulating online, if a product carries a dose you don't recognise, that's a signal to stop and verify. You can check any online pharmacy's registration at the GPhC pharmacy register before purchasing anything.

The short version: 4.8mg Wegovy does not exist. The search likely reflects curiosity about higher doses, and there is a genuinely interesting answer to that, covered below.

What are the actual Wegovy doses, and how does titration work?

Treatment begins at 0.25mg weekly, a starting dose whose job is acclimatisation rather than significant weight loss. From there, the prescriber moves the patient up roughly every four weeks, to 0.5mg, then 1mg, then 1.7mg, then 2.4mg. That last step has historically been the maintenance dose.

The titration pace can slow if side effects are problematic. Nausea, loose stools and stomach discomfort are the most commonly reported issues, particularly in the first few weeks or after a step up. These tend to settle as the body adjusts, but a prescriber may hold a dose for longer than four weeks if needed. The mechanism behind appetite changes on semaglutide (including effects on gastric emptying) explains why this adjustment period matters.

In the STEP 1 clinical trial, which followed 1,961 adults over 68 weeks at the 2.4mg maintenance dose, average body-weight reduction was around 15% compared with placebo. That figure comes from the STEP 1 paper published in the New England Journal of Medicine and is the most widely cited benchmark for this medicine at standard maintenance dosing.

Since April 2026, the schedule has an additional step: the MHRA approved a 7.2mg single-dose pen, making a higher maintenance dose available for adults with a BMI of 30 or above. This is now the ceiling of the licensed Wegovy injection range in the UK. If you're wondering about dose options above 2.4mg, that's the one to ask about at consultation, not a theoretical 4.8mg.

Does a higher dose always mean better results?

Not automatically, and this is where clinical judgment matters most. Trials of the 7.2mg dose reported average weight loss of around 20.7% over 72 weeks, which is meaningfully greater than the 2.4mg figure. But that result came from participants who tolerated the higher dose throughout, and tolerability varies considerably from person to person.

The prescriber's role is to find the dose where clinical benefit and tolerability are in balance for you specifically. Someone who experiences significant nausea at 1.7mg may be held there rather than pushed to 2.4mg. Someone who has reached 2.4mg without difficulty and met the eligibility criteria might, in time, move to 7.2mg. Neither path is better in the abstract; both depend on what your body does.

Cost is also part of the picture. Higher doses carry higher list prices, and that's worth factoring into a longer-term plan. The guide to sourcing Wegovy through a regulated UK pharmacy explains what a legitimate private prescription includes and why price alone is a poor guide to value for a prescription medicine.

For context on how semaglutide compares across the dose range, the page on 8mg semaglutide covers a related query about strengths that sit outside the standard Wegovy ladder.

How would I find out which Wegovy dose is right for me?

The starting point is always a clinical assessment. In the UK, Wegovy is a prescription-only medicine, which means a GPhC-registered prescriber must review your health history, current medicines, BMI and any relevant conditions before any dose is issued. The assessment also covers contraindications, there are people for whom semaglutide is not appropriate, including those who are pregnant, breastfeeding or planning to conceive, and those under 18.

At nume, every consultation is read by a named prescriber on the day it's submitted. There's no algorithm making the call. If you're clinically suitable, treatment is dispatched the same day for next-working-day delivery, and our prescribers are available seven days a week for follow-up. The weight-loss treatments page is where consultations begin.

If you're already on semaglutide elsewhere and have questions about your current dose or a possible step up, reaching the team is straightforward, or browse the FAQs for answers to common queries about transferring treatment. The about us page has more on how nume's clinical model is structured if you're weighing up providers.